Vertex Pharmaceuticals Inc. revenue by year
Over the 10 fiscal years shown, revenue went from $1.70B (year ended Dec 31, 2016) to $12.00B (year ended Dec 31, 2025), a compound annual growth rate of 24.2%. The fastest growth was +49.1% in the year ended Dec 31, 2020; the weakest year was +8.9% (year ended Dec 31, 2025).
Annual revenue
| Fiscal year ended | Revenue (USD) | Change | XBRL concept | Reported in |
|---|---|---|---|---|
| Dec 31, 2025 | $12.00B | +8.9% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 13, 2026 |
| Dec 31, 2024 | $11.02B | +11.7% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 13, 2026 |
| Dec 31, 2023 | $9.87B | +10.5% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 13, 2026 |
| Dec 31, 2022 | $8.93B | +17.9% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 13, 2025 |
| Dec 31, 2021 | $7.57B | +22.1% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 15, 2024 |
| Dec 31, 2020 | $6.21B | +49.1% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 10, 2023 |
| Dec 31, 2019 | $4.16B | +36.6% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 9, 2022 |
| Dec 31, 2018 | $3.05B | +22.5% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 11, 2021 |
| Dec 31, 2017 | $2.49B | +46.2% | Revenues | 10-K filed Feb 15, 2018 |
| Dec 31, 2016 | $1.70B | +64.9% | Revenues | 10-K filed Feb 15, 2018 |
Vertex Pharmaceuticals Inc. reported revenue under 2 different XBRL concepts across these years (often after the 2018 change in revenue-recognition rules, ASC 606). Each row shows the concept used, so you can judge comparability.
Quarterly revenue
Quarters reported in 10-Q filings. Fourth quarters are usually reported only inside the annual 10-K, so they are not listed separately here; we do not estimate them.
| Quarter | Revenue (USD) | vs same quarter a year earlier | Source |
|---|---|---|---|
| 3 months ended Sep 30, 2026 | $3.44B | +11.8% | 10-Q filed Nov 3, 2026 |
| 3 months ended Jun 30, 2026 | $3.33B | +12.5% | 10-Q filed Aug 4, 2026 |
| 3 months ended Mar 31, 2026 | $2.99B | +7.8% | 10-Q filed May 5, 2026 |
| 3 months ended Sep 30, 2025 | $3.08B | +11.0% | 10-Q filed Nov 3, 2026 |
| 3 months ended Jun 30, 2025 | $2.96B | +12.1% | 10-Q filed Aug 4, 2026 |
| 3 months ended Mar 31, 2025 | $2.77B | +3.0% | 10-Q filed May 5, 2026 |
| 3 months ended Sep 30, 2024 | $2.77B | +11.6% | 10-Q filed Nov 4, 2025 |
| 3 months ended Jun 30, 2024 | $2.65B | +6.1% | 10-Q filed Aug 5, 2025 |
Source: SEC EDGAR XBRL company facts for CIK 875320 (raw data). Most recent filing in this dataset: 10-Q filed Nov 3, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.